Vivos Inc (RDGL)

[DULLMANRUNNING]

NEW YORK, May 4, 2015 /PRNewswire/ -- Advanced Medical Isotope Corp. (OTCBB: ADMD) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, recently announced the initiation of a capital restructuring plan in which $5 million of long term debt was converted into a newly designated series of equity based convertible preferred stock. ADMD believes that these actions will have a positive impact on the Company's balance sheet, potentially eliminating up to $800,000 of convertible debt, potentially eliminating a substantial portion of the warrants outstanding and potentially eliminating a substantial amount of the nearly $11 million of derivative liabilities currently reflected on AMIC's balance sheet.

Strengthening the balance sheet is of top importance for this microcap biotech as the company prepares for commercialization of its lead device for brachytherapy therapeutic applications. ADMD's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.

For a more detailed research report with analyst comments and recommendation on Advanced Medical Isotope Corp. please follow the link. There is no cost obligation required to view analyst brief.

http://bit.ly/--ADMD--AnalystReport

Copy and paste to browser may be required.

This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.



RELATED LINKS
http://www.brokerbanksecurities.com